• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Equillium Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/22/25 5:15:05 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EQ alert in real time by email
    8-K
    NASDAQ false 0001746466 0001746466 2025-05-21 2025-05-21
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 21, 2025

     

     

    Equillium, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-38692   82-1554746

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    2223 Avenida de la Playa  
    Suite 105  
    La Jolla, CA   92037
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (858) 240-1200

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.0001 per share   EQ   The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    (e)

    On May 21, 2025, Equillium, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As described in Item 5.07 of this Current Report on Form 8-K (the “Report”), at the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s 2018 Equity Incentive Plan (the “2018 Plan” and the 2018 Plan, as amended, the “2018 Amended Plan”) to, among other things, increase the number of shares of common stock authorized for issuance under the 2018 Plan by 1,781,000 shares. The 2018 Amended Plan was previously approved, subject to stockholder approval, by the Company’s Board of Directors on March 26, 2025. A summary of the principal features of the 2018 Amended Plan are set forth under the heading “Proposal No. 4-Approval of Amendment to the Company’s 2018 Equity Incentive Plan” contained in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 10, 2025, as revised April 30, 2025 (the “2025 Proxy Statement”). The summaries are qualified in their entirety by reference to the 2018 Amended Plan, filed as Exhibit 10.1 to this Report.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    As of April 1, 2025, the record date for the Annual Meeting (the “Record Date”), 35,719,317 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

    A total of 27,708,269 shares of the Company’s common stock were present at the Annual Meeting or represented by proxy, which represents approximately 77.6% of the shares of the Company’s common stock outstanding as of the Record Date.

    Proposal 1. Election of directors.

    The Company’s stockholders elected the three persons listed below as Class I directors, each to serve until the Company’s 2028 Annual Meeting of Stockholders and until their respective successor has been duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:

     

    Name

       Votes For      Votes Withheld      Broker Non-
    Votes
     

    Stephen Connelly, Ph.D.

         20,043,585        787,440        6,877,244  

    Bala S. Manian, Ph.D.

         19,222,114        1,608,911        6,877,244  

    Barbara Troupin, M.D.

         19,832,391        998,634        6,877,244  

    Proposal 2. Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split.

    The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-20, inclusive, with such ratio to be determined in the discretion of the Company’s Board of Directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s Board of Directors in its sole discretion. The final voting results are as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    25,643,102   1,473,553   591,614   0

    Proposal 3. Ratification of the appointment of the independent registered public accounting firm.

    The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results are as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    26,610,815   485,958   611,496   0


    Proposal 4. Approval of an amendment to the Company’s 2018 Equity Incentive Plan.

    The Company’s stockholders approved the 2018 Amended Plan to, among other things, increase the number of shares of common stock authorized for issuance under the plan by 1,781,000 shares. The final voting results are as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    17,935,157   2,300,322   595,546   6,877,244

     

    Item 9.01

    Financial Statements and Exhibits

    (d) Exhibits

     

    Exhibit

    Number

      

    Description

    10.1

      

    Equillium, Inc. 2018 Equity Incentive Plan, as amended.

    104

      

    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

       

    EQUILLIUM, INC.

    Date: May 22, 2025

       

    By:

     

    /s/ Bruce D. Steel

         

    Bruce D. Steel

         

    President and Chief Executive Officer

    Get the next $EQ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EQ

    DatePrice TargetRatingAnalyst
    3/28/2025$3.00 → $1.00Outperform → Market Perform
    Leerink Partners
    1/5/2022$18.00 → $14.00Outperform
    SVB Leerink
    10/29/2021$12.00Buy
    Stifel
    9/15/2021$14.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $EQ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

      EQ504 protects against gut damage in a mouse model of ulcerative colitis EQ504 increases Treg stability and function while suppressing pathogenic Th17 responses EQ504 promotes healing of intestinal epithelial cells by promoting anti-inflammatory cytokines Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu, Hawaii, May 3 – 7. "Decades of independent re

      5/6/25 8:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

      EQ504 targets the aryl hydrocarbon receptor, a clinically validated pathway in the treatment of both skin and gastrointestinal diseases EQ504 has a unique, multi-modal, non-immunosuppressive mechanism of action that is complementary to other immuno-inflammatory therapeutics EQ504 data to be presented in three poster presentations next week at the annual meeting of the American Association of Immunologists (AAI) Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced the advancement of a novel and potent aryl hydrocarbon receptor

      5/1/25 8:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium Announces Feedback from the U.S. Food and Drug Administration

      Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that the company has received feedback from its Type D meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for Accelerated Approval, as well as the company's filing for Breakthrough Therapy designation for itolizumab for first-line treatment of acute graft-versus-host disease (aGVHD). The FDA declined to grant Breakthrough Therapy designation or support an Accelerated Approval pathway based on the EQUATOR study data. The FDA highlighted

      4/24/25 9:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQ
    SEC Filings

    See more
    • Equillium Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Equillium, Inc. (0001746466) (Filer)

      6/13/25 4:05:42 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Equillium Inc.

      144 - Equillium, Inc. (0001746466) (Subject)

      6/12/25 4:19:18 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Equillium, Inc. (0001746466) (Filer)

      5/22/25 5:15:05 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Equillium downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Equillium from Outperform to Market Perform and set a new price target of $1.00 from $3.00 previously

      3/28/25 8:14:37 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Equillium with a new price target

      SVB Leerink reiterated coverage of Equillium with a rating of Outperform and set a new price target of $14.00 from $18.00 previously

      1/5/22 6:36:04 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel resumed coverage on Equillium with a new price target

      Stifel resumed coverage of Equillium with a rating of Buy and set a new price target of $12.00

      10/29/21 8:33:13 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQ
    Leadership Updates

    Live Leadership Updates

    See more
    • Equillium to be included in the Russell Microcap® Index

      Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and va

      6/12/24 8:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

      -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

      10/23/23 8:00:00 AM ET
      $CSTL
      $EQ
      $ICPT
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Equillium Announces Appointment of Barbara Troupin to Board of Directors

      Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the appointment of Barbara Troupin, M.D., to the Equillium Board of Directors. Dr. Troupin will serve as a member of the Nominating and Corporate Governance Committee of the Board. "We are very happy to welcome Dr. Barbara Troupin to the Equillium Board," said Dan Bradbury, chairman of the board of directors of Equillium. "Her experience building and leading clinical development, medical and regulatory affairs functions, as well as her background in global strategy and medical and com

      3/1/22 8:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Colabuono Peter

      4 - Equillium, Inc. (0001746466) (Issuer)

      5/23/25 1:50:43 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Demski Martha J

      4 - Equillium, Inc. (0001746466) (Issuer)

      5/23/25 1:47:55 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Pruzanski Mark

      4 - Equillium, Inc. (0001746466) (Issuer)

      5/23/25 1:45:29 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Equillium Inc.

      SC 13G/A - Equillium, Inc. (0001746466) (Subject)

      11/14/24 9:50:36 PM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Equillium Inc.

      SC 13G - Equillium, Inc. (0001746466) (Subject)

      1/19/24 6:03:46 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Equillium Inc. (Amendment)

      SC 13G/A - Equillium, Inc. (0001746466) (Subject)

      3/3/23 9:27:36 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQ
    Financials

    Live finance-specific insights

    See more
    • Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

      Treatment with itolizumab did not improve complete or overall response rates at Day 29 Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics

      3/27/25 7:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium Maintains Rights to Itolizumab Following Ono Partnership

      Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium's rights to itolizumab

      10/31/24 7:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

      Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone payments Ono to fund Equillium's continued research and development of itolizumab during the exercise period Conference call and webcast today at 8:30 a.m. ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. ("Ono"), today announced an option and asset purchase agreement through which Ono gains the exclusive option to

      12/6/22 7:00:00 AM ET
      $EQ
      Biotechnology: Pharmaceutical Preparations
      Health Care